{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:40:37Z","timestamp":1790095237726,"version":"4.0.1"},"reference-count":16,"publisher":"American Diabetes Association","issue":"4","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.diabetesjournals.org\/journals\/pages\/license"}],"funder":[{"name":"Caswell Diabetes Institute"},{"name":"NIH","award":["R01DK125513"],"award-info":[{"award-number":["R01DK125513"]}]},{"name":"NIH","award":["U54DK118612-04"],"award-info":[{"award-number":["U54DK118612-04"]}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,4,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>Glucagon-like peptide 1 receptor agonists (GLP-1RA) are widely used for the management of diabetes mellitus (DM), but their efficacy in familial partial lipodystrophy (FPLD) is unknown. In this retrospective study, we evaluated the effect of GLP-1RA in patients with FPLD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                  <jats:p>We analyzed data, reported with SDs, from 14 patients with FPLD (aged 58 \u00b1 12 years; 76.47% female) and 14 patients with type 2 DM (aged 58 \u00b1 13 years; 71% female) before and 6 months after starting GLP-1RA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>We observed reduction in weight (95 \u00b1 23 to 91 \u00b1 22 kg; P = 0.002), BMI (33 \u00b1 6 to 31 \u00b1 6 kg\/m2; P = 0.001), HbA1c (8.2% \u00b1 1.4% to 7.7% \u00b1 1.4%; P = 0.02), and fasting glucose (186 \u00b1 64 to 166 \u00b1 53 mg\/dL; P = 0.04) in patients with FPLD. The change in triglycerides after treatment was greater in the FPLD group compared with the DM group (P = 0.02). We noted acute pancreatitis in two case subjects with FPLD with longer therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>Our study demonstrates the relative safety and effectiveness of GLP-1RA in patients with FPLD.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2337\/dc23-1614","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T18:28:32Z","timestamp":1706812112000},"page":"653-659","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":30,"title":["Efficacy and Safety of Glucagon-Like Peptide 1 Agonists in a Retrospective Study of Patients With Familial Partial Lipodystrophy"],"prefix":"10.2337","volume":"47","author":[{"given":"Maria C.","family":"Foss-Freitas","sequence":"first","affiliation":[{"name":"1Division of Metabolism, Endocrinology & Diabetes, University of Michigan, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salman","family":"Imam","sequence":"additional","affiliation":[{"name":"1Division of Metabolism, Endocrinology & Diabetes, University of Michigan, Ann Arbor, MI"},{"name":"2Mercy Health Anderson Hospital (Family Medicine Residency), Cincinnati, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Neidert","sequence":"additional","affiliation":[{"name":"1Division of Metabolism, Endocrinology & Diabetes, University of Michigan, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anabela Dill","family":"Gomes","sequence":"additional","affiliation":[{"name":"1Division of Metabolism, Endocrinology & Diabetes, University of Michigan, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T.","family":"Broome","sequence":"additional","affiliation":[{"name":"1Division of Metabolism, Endocrinology & Diabetes, University of Michigan, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9171-1144","authenticated-orcid":false,"given":"Elif A.","family":"Oral","sequence":"additional","affiliation":[{"name":"1Division of Metabolism, Endocrinology & Diabetes, University of Michigan, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2024,2,1]]},"reference":[{"key":"2024032517510378600_B1","doi-asserted-by":"crossref","first-page":"310","DOI":"10.4158\/EP09154.RA","article-title":"Clinical classification and treatment of congenital and acquired lipodystrophy","volume":"16","author":"Chan","year":"2010","journal-title":"Endocr Pract"},{"key":"2024032517510378600_B2","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1210\/jc.2011-1159","article-title":"Clinical review: lipodystrophies: genetic and acquired body fat disorders","volume":"96","author":"Garg","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2024032517510378600_B3","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2024032517510378600_B4","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2024032517510378600_B5","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"key":"2024032517510378600_B6","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"2024032517510378600_B7","doi-asserted-by":"crossref","first-page":"e2953","DOI":"10.1210\/clinem\/dgab216","article-title":"Effect of leptin therapy on survival in generalized and partial lipodystrophy: a matched cohort analysis","volume":"106","author":"Cook","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"2024032517510378600_B8","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1111\/dme.13527","article-title":"Insulin secretory defect in familial partial lipodystrophy Type 2 and successful long-term treatment with a glucagon-like peptide 1 receptor agonist","volume":"34","author":"Banning","year":"2017","journal-title":"Diabet Med"},{"key":"2024032517510378600_B9","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1210\/jc.2016-2466","article-title":"The diagnosis and management of lipodystrophy syndromes: a multi-society practice guideline","volume":"101","author":"Brown","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"2024032517510378600_B10","author":"Python Software Foundation","year":"2022"},{"key":"2024032517510378600_B11","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1007\/s12020-019-01862-8","article-title":"Long-term effectiveness and safety of metreleptin in the treatment of patients with partial lipodystrophy","volume":"64","author":"Oral","year":"2019","journal-title":"Endocrine"},{"key":"2024032517510378600_B12","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s12020-018-1589-1","article-title":"Long-term effectiveness and safety of metreleptin in the treatment of patients with generalized lipodystrophy","volume":"60","author":"Brown","year":"2018","journal-title":"Endocrine"},{"key":"2024032517510378600_B13","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/cen.13311","article-title":"Spectrum of disease associated with partial lipodystrophy: lessons from a trial cohort","volume":"86","author":"Ajluni","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2024032517510378600_B14","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13098-017-0226-0","article-title":"Dipeptidyl peptidase-4 levels are increased and partially related to body fat distribution in patients with familial partial lipodystrophy type 2","volume":"9","author":"Valerio","year":"2017","journal-title":"Diabetol Metab Syndr"},{"key":"2024032517510378600_B15","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s11154-011-9170-8","article-title":"Is the GLP-1 system a viable therapeutic target for weight reduction?","volume":"12","author":"Tong","year":"2011","journal-title":"Rev Endocr Metab Disord"},{"key":"2024032517510378600_B16","doi-asserted-by":"crossref","first-page":"e157515","DOI":"10.1172\/JCI157515","article-title":"Suppression of food intake by Glp1r\/Lepr-coexpressing neurons prevents obesity in mouse models","volume":"133","author":"Rupp","year":"2023","journal-title":"J Clin Invest"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/47\/4\/653\/751769\/dc231614.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/47\/4\/653\/751769\/dc231614.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T17:54:44Z","timestamp":1711389284000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/47\/4\/653\/154180\/Efficacy-and-Safety-of-Glucagon-Like-Peptide-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":16,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,2,1]]},"published-print":{"date-parts":[[2024,4,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc23-1614","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,1]]}}}